In summary, the current study may suggest that Notch-Hes1 signaling is participated in the pathogenesis of psoriasis by regulating IL-17A+γδ+T cell expression and IL-17A secretion, and blocking Notch-Hes1 signaling may be a new strategy for immunotherapy of psoriasis. The gene discussed is IL17A; the disease is psoriasis.